home / stock / xers / xers news


XERS News and Press, Xeris Pharmaceuticals Inc. From 02/15/21

Stock Information

Company Name: Xeris Pharmaceuticals Inc.
Stock Symbol: XERS
Market: NASDAQ

Menu

XERS XERS Quote XERS Short XERS News XERS Articles XERS Message Board
Get XERS Alerts

News, Short Squeeze, Breakout and More Instantly...

XERS - The Latest On Xeris Pharmaceuticals

Today, we take an in-depth look at specialty pharmaceutical concern Xeris Pharmaceuticals. The company has two approved products developed using their proprietary technology platform. A full investment analysis is as follows. For further details see: The Latest On Xeris ...

XERS - INO, QS, RIOT and FSR among premarket gainers

Artelo Biosciences (ARTL) +63%.China Liberal Education Holdings Limited (CLEU) +59%.Helius Medical Technologies (HSDT) +29%.Denison Mines Corp. (DNN) +26% on $25M bought deal offering.Xeris Pharmaceuticals (XERS) +25% as EC OK's its Ogluo for severe hypoglycaemia.Inovio Pharmaceutic...

XERS - EC OK's Xeris Pharma's Ogluo for severe hypoglycaemia

Xeris Pharmaceuticals (XERS) jumps 13% premarket in reaction to the announcement that the European Commission ((EC)) has approved Ogluo (glucagon) injection for the treatment of severe hypoglycaemia in pediatric and adult patients with diabetes ages 2 years and above.The marketing a...

XERS - Xeris Pharmaceuticals Receives European Commission Approval of Ogluo(TM) (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus

OGLUO™ Europe’s first and only ready-to-use liquid glucagon for rescue First availability expected in the fourth quarter Approval supported by data from pivotal Phase 3 study Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical...

XERS - Xeris Pharmaceuticals Receives European Commission Approval of Ogluo (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the European Commission (EC) has approved Ogluo (gl...

XERS - Xeris Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeri...

XERS - 5 Penny Stocks To Buy According To Analysts & Price Targets Up To 243%

Are Analysts Right About These Penny Stocks? In this article, we’re going to explore a few things about penny stocks , what they are, and how to do research. We’ll also talk a bit about 5 of these stocks that analysts rate a buy right now. So let’s dive in. ...

XERS - Xeris Pharmaceuticals Announces Distribution Agreement With Megapharm Ltd. to Commercialize Gvoke® in Israel and the Palestinian Authority

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has entered into an exclusive distribution a...

XERS - 4 Penny Stocks To Watch Before 2021 & 2 Jumped Over 200% In Q4

During the second week of December, several penny stocks have rallied in a big way. This is likely due to several key factors that investors should know about. The overarching theme in the market right now and for the past six months has been COVID. It has affected both penny stocks and...

XERS - EMA backs Xeris Pharma's Ogluo as treatment in severe hypoglycaemia, shares +8%

The European Medicines Agency's advisory group CHMP has adopted a positive opinion for Xeris Pharmaceuticals' (XERS) Ogluo (glucagon) recommending Ogluo for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The Europe...

Previous 10 Next 10